Azenta Q2 FY23 revenue $148M, GAAP EPS loss $0.03, guided Q3 below consensus

Azenta, Inc.

2023-Q2 EPS reported -$0.23 revenue$326,767,000

Revenue $148M (+2% YoY; -17% sequentially); non-GAAP diluted EPS ($0.06) vs $0.12 a year ago.
Life Sciences Products revenue $59M (+10% YoY) but B Medical $15M, below expectations due to order delays.
Adjusted EBITDA ($2.4M) vs $19M prior year; expects $15M annual cost savings from realignment.
Realigns into three groups (Multi-Omics, Sample Management, B Medical) effective Oct 1, 2023.
Q3 FY23 guidance: revenue $150-168M; non-GAAP EPS ($0.07)-$0.03; GAAP EPS ($0.29)-($0.19).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Azenta, Inc. reported financial results for the second quarter ended March 31, 2023.

Period: the second quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 9, 2023, Azenta, Inc. (“Azenta” or the “Company”) announced via press release its financial results for the fiscal quarter ended March 31, 2023.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Azenta, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.